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Background: Tuberculosis (TB) remains a major threat to global health. Currently,
diagnosis of active TB is hampered by the lack of specific biomarkers that discriminate
active TB disease from other (lung) diseases or latent TB infection (LTBI). Integrated
human gene expression results have shown that genes encoding complement
components, in particular different C1q chains, were expressed at higher levels in active
TB compared to LTBI.
Methods: C1q protein levels were determined using ELISA in sera from patients, from
geographically distinct populations, with active TB, LTBI as well as disease controls.
Results: Serum levels of C1q were increased in active TB compared to LTBI in four
independent cohorts with an AUC of 0.77 [0.70; 0.83]. After 6 months of TB treatment,
levels of C1q were similar to those of endemic controls, indicating an association with
disease rather than individual genetic predisposition. Importantly, C1q levels in sera of TB
patients were significantly higher as compared to patients with sarcoidosis or pneumonia,
clinically important differential diagnoses. Moreover, exposure to other mycobacteria,
such as Mycobacterium leprae (leprosy patients) or BCG (vaccinees) did not result in
elevated levels of serum C1q. In agreement with the human data, in non-human primates
challenged withMycobacterium tuberculosis, increased serum C1q levels were detected
in animals that developed progressive disease, not in those that controlled the infection.
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Conclusions: In summary, C1q levels are elevated in patients with active TB compared
to LTBI in four independent cohorts. Furthermore, C1q levels from patients with TB
were also elevated compared to patients with sarcoidosis, leprosy and pneumonia.
Additionally, also in NHP we observed increased C1q levels in animals with active
progressive TB, both in serum and in broncho-alveolar lavage. Therefore, we propose
that the addition of C1q to current biomarker panels may provide added value in the
diagnosis of active TB.
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INTRODUCTION
Tuberculosis (TB) is a major global health threat, which is
caused by infection by Mycobacterium tuberculosis (M.tb) (1).
Current estimations indicate that a quarter of the global
population is infected with M.tb, with a life-long risk to develop
active TB disease. Particular regions, such as South-East Asia,
Western-Pacific, and Africa regions account for more than 80%
of infected individuals (2). Annually over 6 million people are
diagnosed with TB disease, a serious and highly contagious
condition, resulting in 1.3 million deaths in 2016 only (1). While
most infected individuals remain asymptomatic latently infected
(LTBI), a minority (5–10%) of these individuals progress to active
TB. Given the high rate of infections with M.tb in some regions
it is important to discriminate infection from disease, which is
difficult with the currently available tests. At present, only M.tb
detection in sputum using smear, PCR or culture is definitive
proof of TB disease. Early diagnosis and treatment of TB disease
is important to reduce transmission of infection and prevent
disease associated mortality (1).
Diagnosis of active TB is made by microbiological or genetic
detection of M.tb in sputum (or other specimens in case of
extrapulmonary TB), but this can be expensive and time-
consuming depending on bacterial burdens or requires complex
methodology and infrastructure. Current immunological tests
can detect infection with M.tb but often fail to discriminate
active disease from latent infection (3). Therefore, there is an
urgent need to identify biomarkers that can discriminate active
and latent TB infection in order to promptly initiate treatment
to prevent mortality and further spread of the pathogen, in
particular in areas where M.tb is highly endemic. Ideally, such
biomarkers should also be able to discriminate between TB and
other respiratory infections that present with similar symptoms
and abnormalities on chest X-rays.
Many studies have identified potential biomarkers that
discriminate active TB from LTBI, or that are predictive of
which individuals will progress to active TB (4–10). Differential
gene expression profiles between patients with TB and LTBI or
other (lung) diseases resulted in identification of an array of
potential biomarkers, such as FCGR1A (11–13) and GBP5 (5,
6, 14). Recently, complement has been highlighted as candidate
biomarker for active TB disease (15–19) also in the presence of
HIV co-infection (20). Most currently identified biomarkers have
been identified at the transcriptomic level; however, easy, robust
markers that can be measured at the protein level would be more
ideal candidates for application in the field. Therefore, validation
of markers previously identified at the mRNA level at the protein
level would provide important insights into the applicability of
such markers in clinical practice.
Next to biomarker studies in humans, there are various
experimental models to study the host-pathogen interaction.
The best available model is the non-human primate model
(NHP), infection of rhesus macaques with M.tb, resulted in TB
disease which closely resembles human TB as they experience
similar lesions and clinical courses as humans, suggesting a
common pathophysiology (21). The NHP model adds important
information on kinetics of disease development following M.tb
infection and can be manipulated with e.g., different dosages of
infection, different infecting strains, but also with vaccines.
The complement system is an important part of the innate
immune system and functions as a proteolytic cascade. The
classical complement pathway is initiated by binding of C1q
to ligands, such as immune complexes. Following the binding
of C1q to ligands, enzymatic processes lead to the release of
inflammation stimulating peptides, C3a and C5a, formation
of the opsonin C3b and formation of the membrane attack
complex, resulting in target cell lysis (22). Furthermore, C1q
can bind several receptors that contribute to other important
functions, such as phagocytosis or myeloid cell modulation,
outside traditional complement system activation (23, 24).
For instance, C1q is involved in neovascularization during
pregnancy, coagulation processes and neurological synapse
function (25). C1q is a 480 kDa protein composed of six
arms, each comprising one A, B and C peptide chain (26).
These three chains are encoded by individual genes, C1QA,
C1QB, and C1QC, located on chromosome 1p. In contrast to
most complement proteins, C1q is not produced by hepatocytes
but mainly by monocyte derived cells, such as macrophages
and immature dendritic cells (27–29) and by mast cells (30).
Increased expression of mRNA for C1q has been associated with
TB disease (16, 19).
Here, we analyzed differential expression of complement
genes in patients with TB. Since in publicly available datasets, C1q
expression was most pronouncedly upregulated, we validated
C1q at the protein level in samples from various patient groups
as a biomarker for active TB. Patients with active TB disease
were compared to latently infected individuals, vaccinnees and
to patients with clinical conditions that are important differential
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diagnoses in clinical practice. Finally, to obtain more insight in
the pathophysiology, kinetic analyses were performed samples
obtained from NHP animal models of TB.
MATERIALS AND METHODS
Patients and Controls
Demographic data and classification of the cohorts are presented
in Table 1. Below we have specified the specific inclusion criteria
per cohort.
Tuberculosis
Smear, GeneXpert or sputum culture positive pulmonary TB
patients, LTBI patients and treated TB patients as well as
endemic controls (in different combinations) were included from
various demographic locations: Italy (31), the Gambia, Korea
and South Africa (Table 1). Patients with active pulmonary TB
disease, referred to as “TB” in the manuscript, were diagnosed
based on local, routine methodology. Active pulmonary TB
was sputum-culture confirmed (BACTECTM, Becton-Dickinson,
USA), or based on positive Xpert Mtb/RIF assay (Cephaid
Inc., Sunnyvale, CA, USA), patients were included within 7
days of TB treatment initiation. Latent TB infection, LTBI, was
determined by Quantiferon TB Gold-in tube positivity (Qiagen,
The Netherlands).
In the cohort from South Africa people suspected for TB were
used as controls, these people were presenting with symptoms
TABLE 1 | Description of the cohorts.
Country Classification N Age mean
(range)
Sex
(%male)
Italy Control 15 38 (25–57) 40
Latent TB 18 37 (21–77) 33
Active TB 18 38 (23–67) 89
Treated TB 17 39 (18–70) 35
The Gambia Control 50 31 (15–60) 30
Active TB 50 34 (17–62) 62
Korea Control 10 23 (21–25) 90
Active TB 10 51 (24–77) 40
South Africa Suspect TB 31 32 (18–56) 26
Active TB 20 32 (19–57) 65
Multiple* Leprosy reactions 53 (18–69) 68
the Netherlands Leprosy
†
33 34 (18–57) 62
Sarcoidosis 50 43 (26–57) 60
Control 80 38 (21–67) 36
BCG vaccinated 12 27 (23–57) 33
Pneumonia (Leiden) 40 66 (23–93) 60
Pneumonia (Nieuwegein) 28 73 (34–91) 57
In the table the different cohorts are described regarding the country of origin of the
samples, the disease classification, and the total number of samples per group as well as
the demographic info on age and sex.
*Nepal, Brasil, Ethiopia.
†
Diagnosis made in the Netherlands.
compatible with active TB but had negative X-ray and negative
sputum cultures for TB. These suspected TB patients were
seen again after 2 months and had recovered spontaneously or
after appropriate (non-TB related) treatment. All TB patients
were HIV-negative, as were the endemic controls. Additionally,
from Italy both LTBI (QuantiFERON TB Gold-In-tube-positive
individuals) and successfully treated TB patients (2–72 months
after end of therapy) were included. TB patients from the Gambia
were followed over time (1, 2, and 6months after diagnosis), until
completion of successful treatment.
Other Mycobacterial Diseases and Vaccination
Leprosy patients (mostly immigrants with mixed ethnic
backgrounds) at diagnosis of primary leprosy were included
in the Netherlands. In addition, patients with type-1 reactions
were enrolled in Brazil, Nepal and Ethiopia. Furthermore, we
measured C1q in healthy Dutch individuals who were vaccinated
with BCG Danish strain 1331 (Statens Serum Institut, Denmark)
and followed over time (32).
Other Pulmonary Diseases
Patients with community acquired pneumonia were included
in the Netherlands, one cohort comprised patients admitted
to the intensive care unit in a tertiary care hospital in Leiden
(one patient was HIV-infected with a normal CD4 count and
one suffered from sarcoidosis) and the other cohort comprised
patients admitted to a hospital ward of a non-academic teaching
hospital in Nieuwegein. From both groups of pneumonia patients
paired samples from the time of diagnosis and after recovery
(10–124 days later) were available. Finally, samples were included
prior to initiation of treatment from sarcoidosis patients in the
Netherlands that had pulmonary involvement.
Additional Control Group
As a reference group we included a panel of Dutch healthy
controls, not suffering from major infections or autoimmune
disease.
Ethics Statement
Blood was obtained from individuals upon signing an informed
consent. All studies comply with the Helsinki declaration.
The use of the samples in this study was approved by local
ethical committees. For Italy, Ethical Committee of the L.
Spallanzani National Institute of Infectious diseases (02/2007
and 72/2015); The Gambia (SCC1333); Korea, Institutional
Review Board for the Protection of Human Subjects at YUHS;
South Africa, Health Research Ethics Committee of the Faculty
of Medicine and Health Sciences at Stellenbosch University
(N13/05/064); Brazil, National Council of Ethics in Research
and UFU Research Ethics Committee (#499/2008); Nepal,
Health Research Council (NHR#751); Ethiopia, Health Research
Ethical Review committee Ethiopia (NERC#RDHE/127-83/08);
The Netherlands leprosy patients, (MEC-2012-589); sarcoidosis
patients, Medical research Ethics Committees United of the
St Antonius (#R05.08A); BCG vaccinated individuals, Leiden
University Medical Center Ethics Committee (P12.087); control
group, (P237/94); pneumonia Leiden (P12.147); pneumonia
Nieuwegein (C-04.03 and R07.12).
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Gene Expression Analysis
Global transcriptomic analyses have been performed to compare
patients with active TB disease with latently infected individuals.
In addition, transcriptomes from patients with TB disease were
compared with patients with other diseases, such as sarcoidosis,
pneumonia or lung cancer (5–7, 33–37). Microarray data from
these studies, publically available in Gene Expression Omnibus
(GEO) (GSE37250, GSE19491, GSE39941, GSE28623, GSE73408,
GSE34608, GSE42834, GSE83456), were retrieved from GEO
and re-analyzed. Several of the studies described multiple
independent cohorts, which we analyzed separately for each
population [from Malawi (2), South Africa (3), United Kingdom
(2), Kenya (only TB vs. LTBI), The Gambia (only TB vs. LTBI),
USA and Germany (only TB vs. other diseases)]. All data were
extracted from GEO and compared in the same way using
GEO2R, thus not relying on the analysis performed in the
original manuscript. GEO2R compared two or more groups
of samples in order to identify genes that are differentially
expressed across experimental or clinical conditions. Here, lists
of differentially expressed genes between TB and LTBI or TB
and other diseases (with a significance of p > 0.05 and a
factorial change of >2 or <0.5) were generated. A list of
complement genes and two reference genes was used to assess
possible differential expression for each individual gene for
each study population. All studies/populations with significant
differential expression for a particular gene between patients
with TB compared to LTBI/other diseases were enumerated and
expressed as the percentage of the total number of comparisons
investigated. E.g., differential expression of C1QA between TB
and LTBI was observed in only 2/9 populations investigated
(22%) whereas C1QB differed in 8/9 populations (88%). For all
populations with significant differential expression, the factorial
change (the difference between gene expression in TB patients
compared to LTBI/other diseases) was calculated and plotted.
Animals
Non-human primate (NHP) serum was available from a biobank
of samples collected from earlier TB studies in healthy, purpose-
bred rhesus macaques (Macaca mulatta) for which ethical
clearance was obtained from the independent ethical authority
according to Dutch law. All housing and animal care procedures
were in compliance with European directive 2010/63/EU, as
well as the “Standard for Humane Care and Use of Laboratory
Animals by Foreign Institutions” provided by the Department
of Health and Human Services of the US National Institutes
of Health (NIH, identification number A5539-01). Longitudinal
banked serum samples were available for C1q analysis. Animals
were non-vaccinated or vaccinated with BCG [BCG Danish 1331
(Statens Serum Institute, Denmark)] (n= 23) and experimentally
infected via bronchoscopic instillation of 500 CFU ofM. Erdman.
Prior to infection and 3, 6, 12, 24, 36, and 52 weeks post-infection
samples were collected and stored. Animals were sacrificed when
reaching early humane endpoints (acute progressors) or after
reaching the pre-defined end-point (52 weeks; non-progressors).
Broncho-alveolar lavage (BAL) samples were available from six
animals infected with 1–7 CFU of M. Erdman prior to infection
and 6 or 12 weeks post-infection.
Detection of C1q by ELISA
C1q levels in sera were measured using an in-house developed
ELISA. Maxisorp plates (nunc) were coated overnight with
mouse anti-human C1q (2204) (38), Nephrology department,
LUMC) in coating buffer (0.1M Na2CO3, 0.1M NaHCO3,
pH9.6). Plates were washed and blocked with PBS/1%BSA
for 1 h at 37◦C. After washing, a serial dilution of a pool
of normal human serum (NHS) was applied as a standard
and samples were added in dilution to the plate, all in
duplicate, and incubated for 1 h at 37◦C. Human sera were
diluted 1:8,000 and NHP sera 1:4,000, the BAL fluids were
diluted 1:1. After washing, plates were incubated with rabbit
anti-human C1q (Dako cat#A0136) for 1 h at 37◦C and for
detection a goat anti-rabbit HRP (Dako cat#P0448) was used
which was also incubated for 1 h at 37◦C. All washing steps
were performed with PBS/1%BSA/0.05%Tween. Plates were
stained using ABTS and measured at absorbance of 415 nm, the
measured C1q is expressed in µg/mL as compared to a C1q
standard.
Immunohistochemical Staining of Lung
Tissue for C1q
Samples were collected at autopsy from patients with
fatal TB disease (n = 3), fatal pneumonia patients (n =
4) and a control that died of vascular disease (n = 1)
at the National Institute for Infectious Diseases, Rome,
Italy under local ethical approval (72/2015). Paraffin
sections of 4µm thickness were subjected to heat-induced
antigen retrieval using tris/EDTA (pH 9.0) at 96◦C for
30min, and then stained with rabbit anti-human C1q
(1:1,000; Dako cat#A0136) in PBS/1%BSA for 1 h at room
temperature, followed by an anti-rabbit Envision (Dako)
HRP conjugated antibody also for 1 h at room temperature,
with DAB+ as the chromogen. Negative control rabbit
immunoglobulin fraction (Dako) was used as a negative
control in the same concentration as the primary antibody.
Sections were counterstained with Haematoxylin (Klinipath;
4085.9001).
Statistics
Statistical analyses were carried out using SPSS statistics version
23 (IBM) or Graphpad Prism version 7. To compare C1q levels
the Mann-Whitney U test, Kruskall-Wallis and Dunn’s multiple
comparisons test were used. In all graphs the median is shown
unless indicated otherwise. Receiver operating characteristic
(ROC) analysis was performed to assess the sensitivity and
specificity of C1q as biomarker and was expressed as Area Under
the Curve (AUC).
RESULTS
C1Q Expression Is Upregulated in Patients
With Active TB Disease
Publically available microarray data from TB patients were
retrieved from Gene Expression Omnibus, all data were ranked
as differentially expressed between TB patients and either
LTBI or other diseases (5, 7, 33–37). These studies contained
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information from diverse populations (Malawi, South Africa,
United Kingdom, Kenya, The Gambia, USA, and Germany).
A list of complement gene expression patterns was generated
and the number of microarray studies that reported differential
complement gene expression between patients with TB and
LTBI (Figure 1A) or other diseases (Figure 1B) was enumerated.
Complement genes C1QB, SERPING1 were expressed at higher
level (more than 2-fold) in 8/9 (88%) of studies comparing
patients with active TB to LTBI (Figure 1A). C1QCwas expressed
at a higher level in TB patients in 7/9 studies (78%), whereas
C1QA expression was only increased in TB patients in 2/9
studies (22%; Figure 1A). The observed factorial changes in
the expression of these complement genes between TB patients
and LTBI individuals were comparable with the changes as
seen for FCGR1A and GBP5, which were previously described
as promising and highly consistent biomarkers of active TB
(Figure 1C). A similar pattern, although less pronounced, was
seen when comparing TB patients with patients having another
lung-disease (Figures 1B,D). As C1q is abundantly present, easy
to measure and stable, therefore we continued to analyse C1q
protein levels.
C1q Is Significantly Increased in Serum of
TB Patients
C1q protein levels were measured in sera from TB patients and
controls from independent and geographically distinct cohorts
(Figures 2A–D). The levels of C1q were significantly higher
in sera from patients with active TB as compared to their
respective controls in all cohorts: Italy (Figure 2A), The Gambia
(Figure 2B), Korea (Figure 2C) and South Africa (Figure 2D).
LTBI individuals and successfully treated TB patients had serum
C1q levels similar to controls (Figure 2A). Combined analysis of
all TB patients, control groups, LTBI and the successfully treated
TB patients from the different cohorts revealed that serum C1q
protein levels are significantly (p < 0.001) increased in active TB
(Figure 2E).
The Gambian TB patients were followed over time which
allowed us to investigate C1q levels during successful treatment.
At 1 month of treatment the median serum C1q level
was still increased, however, the level of C1q began to
decrease after 2 months (p = 0.0650), resulting in complete
normalization compared to the TB contacts after 6 months
of successful treatment (p < 0.001; Figure 2F). Thus, serum
FIGURE 1 | Differentially expressed complement genes in whole blood tuberculosis transcript signatures. Tuberculosis specific transcript signatures, from various
populations, were investigated for the presence of differentially expressed complement genes using a tuberculosis RNA biomarker database. Publically available
transcriptome data was retrieved from Gene Expression Omnibus (5–7, 33–37) and analyzed using GEO2R. Data were available for nine populations comparing active
TB with LTBI and for 8 populations comparing active TB with other diseases. For each population we determined if the complement family genes were differentially
expressed between TB and LTBI or other diseases. Differential expression was defined as an adjusted p-value <0.05 and more than 2-fold change. Differential
expression of a gene between TB and LTBI or other diseases was expressed as percentage of the total number of populations investigated. The differential expression
of complement genes was scored (A,B) as well as the mean factorial change for the C1q genes, C1QA, C1QB, and C1QC (C,D) for the comparisons TB vs. LTBI
(A,C) and TB vs. other diseases (B,D). As a reference two other highly upregulated potential diagnostic TB markers, FCGR1A, and GBP5, were included in the
analyses.
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FIGURE 2 | C1q serum levels are increased in patients with pulmonary Tuberculosis. C1q levels (µg/ml) were measured with ELISA in sera from TB patients (active
disease) and controls from different cohorts. First the results from the independent and geographically different cohorts are depicted. TB patients from Italy were
compared to Latent TB infected (LTBI), to Past TB (patients that were successfully treated for TB) and to endemic controls (A). TB patients from The Gambia were
compared to TB contacts (B). TB patients from Korea were compared to endemic controls (C). From South Africa the TB patients were compared to patients
suspected for TB but confirmed non-TB (D). Subsequently, data from the cohorts were pooled: control (CTRL) comprises Dutch healthy controls, combined with the
CTRL from Italy and Korea; moreover, healthy individuals prior to vaccination with BCG were included (n = 117). Latent TB infected (LTBI) comprises LTBI from Italy,
TB suspects (confirmed non-TB) from South Africa and TB contacts from the Gambia (n = 100). Active tuberculosis (TB) from Italy, the Gambia, Korea and South
Africa (n = 99); Past TB are patients that were successfully treated for TB and combined the past TB from Italy and the Gambia samples after 6 months of treatment
(n = 71) (E). From the Gambia the TB patients were followed over time during treatment, TB contacts are shown on the right (n = 50) (F). Results were analyzed using
the Mann-Whitney U test, >2 groups Kruskall-Wallis and Dunn’s multiple comparisons test. The treatment months were compared to TB diagnosis with Friedman Test
and Dunn’s multiple comparisons test.
C1q protein levels were significantly elevated in patients
with active TB, and levels decreased to the level of the
control population during successful treatment. This further
indicates that increased C1q levels are associated with active
TB disease and do not reflect genetic variation in C1q
expression.
Vaccination With BCG Does Not Increase
C1q Levels in Serum
To investigate if vaccination with M. bovis BCG, a live
replicating mycobacterium, induced a similar increase in
serum C1q levels, samples were taken before and after
BCG vaccination of healthy Dutch volunteers and C1q levels
were measured (Figure 3). Samples taken at screening and
directly before vaccination showed minimal variation in C1q
levels, reflecting normal variation within individuals. BCG
vaccination did not induce fluctuations in C1q levels larger
than this naturally observed variation. Thus, BCG vaccination
did not increase C1q levels in contrast to what was observed
in TB disease, despite the presence of live, replicating
mycobacteria.
C1q Levels Are Increased in Active TB
Compared to Other Diseases
To investigate the specificity of increased C1q levels for active
TB, sera from patients with other diseases with similar symptoms
and radiological abnormalities (pneumonia, sarcoidosis) and
sera from patients with other mycobacterial disease [leprosy,
primary disease or type 1 (acute pro-inflammatory) reactions]
were analyzed. C1q levels in sera from patients with TB were
significantly higher compared to sera from patients with leprosy,
pneumonia or sarcoidosis (Figure 4A, data from TB patients
and controls same as used in Figure 2E). Some individual
leprosy patients had C1q protein levels above the median of TB
patients but this was not related to either primary disease or
having type I reactions (Supplementary Figure E1A). Patients
with sarcoidosis showed a slight increase in C1q levels compared
to the controls. In contrast, patients with community acquired
pneumonia showed a significant decrease in C1q levels compared
to the control population. The reduced levels observed in patients
with pneumonia at diagnosis was associated with the disease state
since samples included from the same individuals at later time
points had normal C1q levels (Supplementary Figures E1B,C).
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FIGURE 3 | BCG vaccination does not induce a similar C1q upregulation.
Healthy individuals who were vaccinated with BCG (n = 13), were followed
over time and C1q serum levels were measured. C1q levels were first
calculated to µg/ml and for each individual set to 1 using the measurement of
the C1q level before vaccination. The dotted lines indicate the variation that is
present in C1q levels at the time of screening and prior to vaccination.
To assess the value of C1q as possible TB biomarker, the
sensitivity, specificity and the positive likelihood ratio (LR+)
were calculated fromC1q concentration cut-offs (10).With a cut-
off at the 95th percentile of the control population (300.2µg/ml
C1q) the sensitivity is 42% with a specificity of 91% resulting in
a LR+ of 4.96. Application of a cut-off at the maximum of the
control population (347.6µg/ml) resulted in a sensitivity of 29%
and a specificity of 97% resulting in a LR+ of 8.99. The capacity of
serum C1q to discriminate active TB from LTBI, pneumonia and
sarcoidosis was also analyzed using ROC analyses and expressed
as AUC (Figures 4B,C). The AUC of C1q levels for TB vs. LTBI
was 0.77, for TB vs. sarcoidosis 0.69, and for TB vs. pneumonia
even an AUC of 0.93 was achieved.
C1q Is Locally Present in the Lungs of TB
Patients
So far circulating RNA and protein levels of C1q have been
analyzed, which reflect the systemic response to TB. Additionally,
we analyzed the local C1q production or deposition in response
to M.tb infection by staining lung tissue. Staining lung tissue
from a control revealed scarce C1q staining with only few C1q
positive macrophage-like cells in the lung parenchyma and in
the intra-alveolar space (Figure 5). In contrast, lung tissue of
fatal TB patients revealed, next to the intra-alveolar C1q positive
cells also a pronounced C1q staining both in the necrotic centers
of the granulomas and in the surrounding lung tissue with
predominantly macrophage-like cells staining positive. Lung-
tissue from patients that succumbed from pneumonia showed
C1q staining predominantly in the intra-alveolar space. Staining
of consecutive sections with an isotype control did not reveal
any staining, also not in the necrotic centers, confirming specific
staining for C1q. Thus, C1q protein is locally detected at an
increased level in the lungs of TB patients (n = 3) compared to
tissue samples from a non-pulmonary disease control (n = 1) or
pneumonia patients (n= 4).
Non-human Primates With Active TB
Disease Also Display Increased Serum C1q
Levels
Non-human primate (NHP) M.tb infection models are widely
used to study pathogen-host interactions and for pre-clinical
evaluation of vaccine candidates (39). After infection, rhesus
macaques develop TB disease which closely resembles human
TB in most aspects. Sera banked over the course of a long-term
follow-up study in rhesus macaques were used to determine C1q
levels after experimental M.tb infection. 14 Out of 16 animals
with active progressive disease, that had reached an early humane
endpoint due to exacerbation of TB disease, had increased C1q
levels compared to their baseline C1q levels before infection
(Figure 6A). Such a rise in C1q levels was absent in six out of
seven animals that did not develop overt disease, but controlled
the infection over an extended period of time up to 1 year
post-infection (Figure 6A). Additionally, in an separate cohort
of M.tb infected NHPs we detected elevated C1q levels in five
out of six broncho-alveolar lavage (BAL) fluid samples taken
before necropsy, while no C1q could be detected in paired
BAL fluids taken prior to infection (Figure 6B). The observed
differences could not be explained by any differences in BAL
volume recovery and thus these data reflect a true local increase
in C1q afterM.tb infection.
DISCUSSION
The accurate and fast identification of patients with active TB
remains challenging, largely because of limitations in the current
diagnostic tools to differentiate active TB from other diseases,
as well as LTBI. Extensive searches for biomarkers that can
discriminate active TB from other diseases with similar clinical
presentation as well as from LTBI have been recently reported
(3, 40). Several studies reported genes encoding for complement
components to be upregulated in TB (15–19). Here, we compiled
available genome wide gene expression data for TB compared
to LTBI and TB compared to other lung diseases (5–7, 33–
37) and observed that in particular C1q encoding genes were
highly upregulated. Interestingly, these observations were made
in studies using RNA from whole blood, indicating increased
transcription of C1q genes in circulating blood cells, most likely
monocytes/macrophages. Since C1q is not a typical acute-phase
protein we were interested to confirm and validate these findings
at the protein level. We have therefore measured C1q protein
levels in serum and confirmed increased levels in patients with
active TB, but not in other diseases with a similar clinical
presentation, such as pneumonia or sarcoidosis, or mycobacterial
exposure. C1q protein is also present in the lung tissue of
deceased TB patients. The increased levels of local and circulating
C1q in TB were replicated independently in a NHP TB infection
model.
Literature suggests that expression of the three C1q genes
C1QA, C1QB, and C1QC is regulated in a similar manner (41).
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FIGURE 4 | Increased C1q serum levels are associated with TB. C1q was measured in various cohorts by ELISA. The pooled data from Figure 2E control population
(CTRL) and TB (active disease) is now compared to other diseases: leprosy (n = 86), sarcoidosis (n = 50), and community acquired pneumonia (n = 68) (A).
Differences between groups were analyzed using Kruskall-Wallis and Dunn’s multiple comparisons test. Both the leprosy and the pneumonia cohort comprise two
patient groups. The data for these individual groups is visualized in Supplementary Figure E1. ROC analysis of the ability of C1q to distinguish TB from CTRL, LTBI,
sarcoidosis, and pneumonia are plotted together (B) and for all comparisons the Area Under the Curve (AUC) was calculated and summarized in the table (C).
However, upon IFNγ-stimulation upregulation ofC1QB is higher
than C1QC, which is higher than C1QA (41). Similarly, our data
also showed upregulated expression of C1QB and C1QC genes
and C1QA was less frequently observed in active TB, also in the
analysis from Cai et al. the extend of increase in the expression
of C1QA was less pronounced as compared to the increase in
expression of C1QB and C1QC. Since C1q protein production
requires equal ratios of all three chains, the detected increase in
C1q protein levels in TB patients indicates that all chains are
expressed. The low detection of C1QAmay thus be technical and
reflect a poor capture of C1QA expression on the microarrays in
general.
Wemeasured C1q protein levels in four different geographical
cohorts from Italy, The Gambia, Korea and South Africa. C1q
levels were increased in patients with active TB compared to all
relevant control populations. Importantly, treatment normalized
serum C1q levels to those of endemic controls, indicating that
the upregulation of C1q was associated with the disease and not
intrinsic to the individuals. BCG vaccination, although being a
live replicating mycobacterial vaccine, did not induce increased
C1q levels. Although leucocytes of patients with leprosy reactions
were reported to express increased levels of C1QA, B, and C (42),
the cohorts analyzed here did not universal show increased serum
C1q levels. Individual patients might have somewhat increased
levels, both in this study (type 1 reaction) and a previous report
(type 2 reaction) (43), which warrants more detailed analyses.We
speculate that the different pathophysiologies of TB and leprosy,
in particular the different levels of systemic inflammation and
immune activation which are generally higher in active TB than
in leprosy are responsible for the difference in C1q levels between
the two diseases, even though both are caused by pathogenic
mycobacteria.
To further evaluate the potential of C1q as a biomarker for
active TB, C1q levels were compared to those of disease relevant
controls as patients with untreated pulmonary sarcoidosis or
pneumonia. Patients with TB had significantly higher circulating
C1q levels as compared to patients with sarcoidosis or patients
with pneumonia. Thus, the upregulation of C1q likely does
not reflect a general response to inflammation. Patients with
pneumonia rather had decreased C1q levels compared to
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FIGURE 5 | C1q accumulates in lung tissue of patients with fatal pulmonary TB. Lung tissue, obtained at autopsy from a non-pulmonary disease control (n = 1), fatal
active TB patients (n = 3), or patients with lethal pneumonia (n = 3) were stained for the presence of C1q. The left column shows the presence of C1q in a section of
the control, two active TB patients and a pneumonia patient, scale bar at 200µm. The middle column shows the same samples stained for C1q, while the right
column shows consecutive tissue slides stained with a matched control antibody, scale bars at 50µm. Necrotic areas that stain positive for C1q are highlighted with
an asterisk (*) and individual cells that stain positive for C1q are highlighted with arrows.
FIGURE 6 | Rhesus macaques infected with Mycobacterium tuberculosis display increased levels of C1q in serum and broncho-alveolar lavage fluid. C1q levels were
measured in serum samples from rhesus macaques (n = 23) which were infected with Mycobacterium tuberculosis and followed over time. C1q levels were first
calculated as Arbitrary Units (AU) per ml after which the C1q level of each animal at baseline was set as 1. Animals which controlled the infection are termed
non-progressors and animals reaching a premature humane endpoint due to active disease progression are termed acute progressors (A). Separately, C1q was
measured in broncho-alveolar lavage (BAL) fluid obtained from animals before and 6 or 12 weeks after infection with M.tb (n = 6) and calculated as AU/ml (B).
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controls. Treatment of pneumonia normalized the levels of
circulating C1q, suggesting that the observed decrease in C1q
is non-genetic and likely associated with the disease process.
ROC analysis indicated that C1q, even as a single marker, readily
discriminated active TB from all other diseases investigated here.
Furthermore, also in a setting of an experimental NHP model of
TB disease we observed in both sera and BAL fluid increased
C1q levels in animals with symptomatic TB disease compared
to the level prior to infection with M.tb. This was not seen in
animals that did not progress to TB disease, suggestion again an
association with TB disease rather than infection only. These data
fully agree with and support the observations described above in
the human cohorts.
Longitudinal follow up of TB patients during treatment
revealed that circulating C1q levels normalized to the level
of endemic controls. However, here protein levels did not
completely normalize until the 6 months time point. Previously
published data showed a rapid decrease in C1qmRNA expression
levels following treatment (16, 19). Cliff et al. show that already
after 1 week of treatment the blood C1q gene expression
decreased (16). Cai et al. reported a significant decrease in
the expression of the C1q genes at 3 months of anti-TB
chemotherapy whereas they also described a reduction in C1qc
protein levels after 6 months (19). Our data presented here
substantially expand the number of populations, including
populations from different regions of the world. Transcriptomic
analysis of genes encoding complement proteins were now
assessed in 9 independent populations from different TB endemic
as well as non-endemic regions, strongly supporting an increase
in expression of C1Q as well as SERPING1 during active
TB disease in cells present in peripheral blood. Moreover, 4
independent cohorts as well as the data obtained in the NHP
model show increased circulating C1q plasma levels during active
TB disease, but not infection. In addition to conforming the data
previously published for a Chinese population (Cai et al.) in 4
different TB cohorts, we also showed the specificity for TB disease
in comparison to clinically important differential diagnoses,
such as sarcoidosis and pneumonia. As C1q is produced by
cells of monocytic origin, it reflects another component of
the immune space compared to most currently applied TB
biomarkers, such as C-reactive protein and IP-10 (44–47). In
addition, C1q levels are technically easy to measure and the
C1q protein is not sensitive to degradation. Therefore, we
hypothesize that addition of C1q to current biomarker panels
or platforms, will have additive value in discrimination of TB
patients.
Low levels of C1q have been reported in several
inflammatory and autoimmune diseases, such as Systemic
Lupus Erythematosus. This is largely the result of C1q
consumption because of immune complex mediated disease
and in some rare cases caused by genetic C1q deficiency (26).
However, the increased levels of C1q, as occur in TB, are
observed very rarely. So far the only other clinical condition
in which increased levels of C1q have been reported is
Kala Azar (48). The mechanism behind the increased C1q
levels observed in TB patients, or the possible functional
consequences for the host are unknown, and will need
further investigation. The availability of the NHP model of
tuberculosis for C1q research, as demonstrated for the first
time in this study, should greatly accelerate and facilitate such
work.
In conclusion, we show here that circulating C1q expression is
increased in 9 different populations with TB disease, moreover,
elevated C1q plasma levels were observed in 4 cohorts of TB
patients compared to LTBI or endemic controls. Specifically,
C1q levels in TB patients were significantly increased compared
clinically relevant diseases, such as sarcoidosis, leprosy and
pneumonia. Moreover, we show that increased C1q levels
decreased to the level of the control population during successful
treatment. In analogy with human TB, C1q also validated
as a biomarker of TB disease in rhesus macaques, in both
serum and BAL. Increased C1q levels were only observed in
animals that progressed to active disease and not in those
that controlled the infection, suggesting a direct association
with disease rather than with infection. Therefore, we propose
that the addition of C1q measurements to current biomarker
panels may provide added value in the diagnosis of active
TB.
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